Agios Pharmaceuticals (AGIO) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Agios Pharmaceuticals is the larger company by market cap ($1.90 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | GENB |
|---|---|---|
| Share price | $31.81 | $14.34 |
| Market cap | $1.90B | $1.84B |
| 1-day change | -0.34% | +2.50% |
| YTD return | +16.86% | — |
| 1-year return | -25.03% | — |
| 5-year return | -31.27% | — |
| EPS (TTM) | $-7.01 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | — |
| Revenue growth (YoY) | +48.03% | — |
| Net income (latest FY) | $-412.78M | — |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | — |
| Net margin | -764.01% | — |
| 52-week high | $46.00 | $22.67 |
| 52-week low | $22.24 | $11.00 |
| Distance from 52-week high | -30.85% | -36.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.61% | +88.28% |
| Average volume | 1.08M | 1.05M |
| Shares outstanding | 59.70M | 128.35M |
| Employees | 539 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
AGIO vs GENB FAQ
Which is bigger, Agios Pharmaceuticals or Generate Biomedicines?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.90B compared with $1.84B for Generate Biomedicines (GENB).
Are Agios Pharmaceuticals and Generate Biomedicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.